Will HSBC Holdings plc or GlaxoSmithKline plc continue to offer sky-high yields?

HSBC Holdings (LON: HSBA) and GlaxoSmithKline (LON: GSK) give you base rate-busting yields but Harvey Jones questions whether they’re sustainable.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These are glory days for income seekers with a host of FTSE 100 big-name stocks offering yields of 5%, 6%, 7% or even more. With the average easy-access savings account now paying just 0.47%, according to Moneyfacts, they offer an invaluable income stream.

The difference between cash and a dividend is that the latter isn’t guaranteed, so you need to check how sustainable the payouts are. HSBC Holdings (LSE: HSBA) and GlaxoSmithKline (LSE: GSK) both offer amazing yields today, but will you still love them tomorrow?

Hold on

HSBC was seen as a great way to play China and emerging markets, until Asia hit the skids. This left HSBC high and dry and the last five years have been pretty torrid for investors, with the share price down 35% in that time. There ‘s been no sign of a reprieve lately, but the volatile share price has driven the yield, with the stock now offering an incredible income of 7.97%.

An 18% year-on-year drop in first-quarter profits to $5.4bn suggests there’s no easy road back for the struggling bank, as up-and-down stock markets hit its equity business, while falling oil and commodity prices drive rising impairments among clients in the sector.

Chief executive Stuart Gulliver is edging the business away from volatile investment banking to focus on UK retail and Hong Kong and Chinese commercial banking. The restructuring will take time and earnings per share (EPS) are forecast to drop 9% this year, but far-sighted investors can look forward to a reversal in 2017, with a forecast 8% rise. Dividend cover is still 1.3 times and although it has been shrinking lately the payout looks safe for now, supported by a strong balance sheet. Now we just hope that Gulliver’s travels prove rewarding.

Cover required

Pharmaceutical giant GlaxoSmithKline has long been seen as one of the most stable dividend payers on the FTSE 100 but lately its share price performance has been rocky. The income stream, however, has been as reliable as ever, and the stock currently yields a generous 5.66%. When people moan about falling savings rates I want to shout from the rooftops about income stocks like these, despite the capital risk.

Dividend cover has slipped to 0.9, which is starting to look a little thin. The last time Glaxo hiked the dividend was in 2014, when it raised it from 78p to 80p a share. It has stuck at that level since and will continue to do so, with management pledging to pay an annual ordinary dividend of 80p in both 2016 and 2017. So that gives you some security in the near term.

Glaxo needs to generate higher earnings to sustain the dividend beyond that, which is a challenge with EPS falling each of the last four years, including a 21% drop most recently in 2015. However, the outlook is more positive, with EPS forecast to rise by 16% in 2016 and 5% next year. Management is wisely looking to reduce its dependence on blockbuster drugs by diversifying into vaccines and consumer health. If this strategy proves a success, investors can finally look forward to further dividend progression. Shame it’s so expensive at 19 times earnings, which makes HSBC look cheap at 9.72 times.

Neither HSBC nor Glaxo are surefire dividend bets, but as the hunt for yield intensifies, the long-term rewards far outweigh the risks.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended HSBC Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »